Article

FFR-Guided PCI Not Shown to Be Noninferior to CABG in Patients with Three-Vessel CAD

Author(s):

Data show the 1-year incidence of the composite primary endpoint was 10.6% among patients randomized to FFR-guided PCI and 6.9% in CABG.

William F. Fearon, MD

William F. Fearon, MD

Although patients with three-vessel coronary artery disease (CAD) have been shown to have better outcomes with coronary-artery bypass grafting (CABG) compared to percutaneous coronary intervention (PCI), there is little data in which PCI is guided by a measurement of fractional flow reserve.

As a result, a recent study explored CABG compared to FFR-guided PCI in patients with three-vessel CAD, with a primary endpoint as the occurrence within 1 year of a major adverse cardiac or cerebrovascular event.

Led by William F. Fearon, MD, Stanford Cardiovascular Institute, the team of investigators found FFR-guided PCI was not found to be noninferior to CABG in this patient population.

The Study

The study encompassed a multicenter, international, non-inferiority trial, in which patients with three-vessel CAD were randomly assigned to undergo CABG or FFR-guided PCI with current-generation zotarolimus-eluting stents.

Primary endpoints were considered the occurrence within 1 year of a major adverse cardiac or cerebrovascular event, defined as death from any cause, myocardial infarction, stroke, or repeat revascularization. Secondary endpoints were defined as a composite of death, myocardial infarction, or stroke, while safety was additionally assessed.

Investigators prespectified the non inferiority of FFR-guided PCI to CABG as an upper boundary of less than 1.65 for the 95% confidence interval (CI) of the hazard ratio (HR).

Data

Overall, a total of 1500 patients underwent randomization throughout 48 centers. Data show patients assigned to undergo PCI received a mean of 3.7±1.9 stents, while patients assigned to undergo CABG received 3.4±1.0 distal anastomoses.

They observed the 1-year incidence of the composite primary endpoint was 10.6% among patients randomized to undergo FFR-guided PCI and 6.9% among those assigned to undergo CABG (HR, 1.5; 95% CI, 1.1 - 2.2). This was not consistent with the noninferiority of FFR-guided PCI (P = .35 for noninferiority).

Further, the incidence of death, myocardial infarction, or stroke was 7.3% in the FFR-guided PCI group and 5.2% in the CABG group (HR, 1.4; 95% CI, 0.9 - 2.1).

Lastly, incidences of major bleeding, arrhythmia, and acute kidney injury were higher in the CABG group compared to the FFR-guided PCI group.

Takeaways

“In patients with three-vessel coronary artery disease, FFR-guided PCI was not found to be noninferior to CABG with respect to the incidence of a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year,” investigators wrote.

The study, “Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery,” was published in The New England Journal of Medicine.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
© 2024 MJH Life Sciences

All rights reserved.